PathoFinder is a privately owned molecular diagnostics company founded by Guus Simons, PhD, in 2004. The company focuses on the development and commercialization of comprehensive panels, with special emphasis on infectious diseases. PathoFinder's proprietary 2SmartFinder® technology enables the detection and differentiation of up to 24 viral, bacterial, fungal and parasitic pathogens in a single assay. PathoFinder is based in Maastricht, The Netherlands.
To be a global leader in better molecular diagnostic solutions.
We improve patient outcomes by innovating advanced molecular diagnostics.
PathoFinder has an EN ISO 13485:2016 certified Quality Management System for the design and development, manufacturing and distribution of In-Vitro Diagnostics for infectious diseases. In addition, we are certified as meeting the requirements of Directive 98/79/EC on IVD Medical Devices. Quality Control for Molecular Diagnostics (QCMD,
www.qcmd.org) is an international External Quality Assessment (EQA) provider for molecular diagnosis of infectious agents. QCMD has an extensive EQA portfolio with a wide range of clinically relevant infectious diseases and includes schemes for the assessment of microbial load, genotyping and drug resistance. In the past years PathoFinder has successfully participated in all applicable EQA programs for both the 2SmartFinder® and RealAccurate® products. Details of these tests are available on request.
